期刊文献+

生理药代动力学模型及其在健康风险评价中的应用研究进展 被引量:7

Research advances of the physiologically based pharmacokinetic(PBPK) models and their applications in health risk assessment
下载PDF
导出
摘要 生理药代动力学(Physiologically Based Pharmacokinetic,PBPK)模型在健康风险评估中的应用逐渐成为研究的焦点。简要阐述了PBPK模型的定义及发展历程,在此基础上详细介绍了PBPK模型建立的过程及其在致癌风险评估、混合物健康风险评估中的应用。最后,总结了该模型在健康风险评估应用中的受限因素,提出跨学科合作有利于解决这些受限因素,从而进一步推进该模型在混合物健康风险评价中的应用。 The present paper is inclined to bring about a research review on the advances in making the physiologically based pharmacokinetic(PBPK) models and their applications to the health risk assessment.As is known,the PBPK models are very important and useful mathematical models based on the physiology,biochemistry,and anatomy of the organisms.Such models tend to adopt the algebraic and differential equations for describing the uptake,distribution,metabolism,and excretion of chemicals according to the law of mass conservation and,for such models help to reduce the uncertainty but increase the accuracy of the health risk assessment.And it is for the above reasons that the science giants in the line have won more attention to the law from the researchers to further develop such models in recent years.However,most of such models have still had their own respective limits,which prevent them from being more widely applied at least in the health risk assessment.In this paper,we would like to make a summary of the detailed modeling process of PBPK,their applications and their confining factors.And we wish to promote more popular application of the PBPK models in the risk assessment.Firstly,we have briefly introduced the definition and research status of PBPK models.Secondly,what we can do is to introduce mainly the detailed modeling process of the models,including the model structure,mathematical equations,the model-building parameters,the solutions to the PBPK modeling equations and validation/calibration.What is more,we have also displayed how to use them in the carcinogenic risk detection and those with the chemical mixtures in this paper.The applications of such models to the carcinogenic risk may include the extrapolation and variability of the interspecies,the routeto-route extrapolation,high-to-low-dose extrapolation,etc.Moreover,we have also provided samples on how to illustrate the application methods.And,finally,it is necessary to point out the application limits of the PBPK models in health risk assessment.Starting from the current research situations,the confining factors mainly include the complex modeling proeess,lack of relevant experimental data,difficulties in the mixed modeling,lack of heavy metal modes,lack of simplified solutions and so on.Therefore,close cooperation and coordination are called for to solve the aforementioned problems through joined efforts so as to promote further applications of the PBPK models to the risk assessment area.
作者 牛志广 臧雪
出处 《安全与环境学报》 CAS CSCD 北大核心 2015年第6期30-34,共5页 Journal of Safety and Environment
基金 天津市应用基础及前沿技术研究计划一般项目(12JCYBJC14600) 新世纪优秀人才支持计划项目
关键词 安全学 毒理学 生理药代动力学模型 建模过程 致癌风险 混合物 健康风险 safety science toxicology physiologically based pharmacokinetic models modeling process carcinogenic risk mixtures health risk
  • 相关文献

参考文献37

  • 1KRISHNAN K, ANDERSEN M E. Physiologically based pharmacokinetic modeling in toxicology[J]. Principles and Methods of Toxicology, 2001, 4: 193-241.
  • 2LINDSTROM F T, GILLETT J W, RODECAP S E. Distribution of HEOD (dieldrin) in mammals: I. Preliminary model[J]. Archives of Environmental Contamination and Toxicology, 1974, 2(1): 9-42.
  • 3ANDERSEN M E, CLEWELL III H J, GARGAS M L, et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride[J]. Toxicology and Applied Pharmacology, 1987, 87(2): 185-205.
  • 4BYCZKOWSKI J Z, FISHER J W. A computer program linking physiologically based pharmacokinetic model with cancer risk assessment for breast-fed infants[J]. Computer Methods and Programs in Biomedicine, 1995, 46(2): 155-163.
  • 5DELIC J I, LILLY P D, MACdONALD A J, et al. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride[J]. Regulatory Toxicology and Pharmacology, 2000, 32(2): 144-155.
  • 6HADDAD S, BéLIVEAU M, TARDIF R, et al. A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures[J]. Toxicological Sciences, 2001, 63(1): 125-131.
  • 7WASON S C, SMITH T J, PERRY M J, et al. Using physiologically-based pharmacokinetic models to incorporate chemical and non-chemical stressors into cumulative risk assessment: a case study of pesticide exposures[J]. International Journal of Environmental Research and Public Health, 2012, 9(5): 1971-1983.
  • 8MEEK M E, BARTON H A, BESSEMS J G, et al. Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment[J]. Regulatory Toxicology and Pharmacology, 2013, 66(1): 116-129.
  • 9U.S. Environmental Protection Agency. Approaches for the application of physiologically based pharmacokinetic ( PBPK ) models and supporting data in risk assessment, EPA/600/R-05/043F[R]. Washington DC: National Center for Environmental Assessment Office of Research and Development, 2006.
  • 10杨杰,鲁荔,杨金燕,田丽燕,唐亚.攀枝花地区土壤及矿物中3种重金属形态及健康风险[J].安全与环境学报,2014,14(1):242-247. 被引量:9

二级参考文献57

  • 1李筱薇,云洪霄,尚晓虹,赵云峰,吴永宁.大米中无机砷的生物可给性体外消化评价模型介绍[J].食品安全质量检测学报,2010,1(1):7-11. 被引量:8
  • 2Ivan Nestorov. Whole body pharmacokinetic models [J]. Clin Pharmacokinet, 2003,42: 883-908.
  • 3Haber LT, Maier A, Zhao Q, et al. Applications of mechanistic data in risk assessment: the past, present, and future[ J ]. Toxicol Sci, 2001,61 : 32-39.
  • 4Kaneko T, Horiuehi J, Sato A. Development of a physiologically based pharmacokinetic model of organic solvent in rats [J]. Pharmacol Res, 2000,42 : 465-470.
  • 5Krishnan K, Johanson G. Physiologically-based pharmacokinetie and toxicokinetic models in cancer risk assessment[J]. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2005,23 : 31-53.
  • 6Hissink EM,Bogaards JJP, Freidig AP, et al. The use of in vitro metabolic parameters and physiologically based pharmacokinetic modeling to explore the risk assessment of trichloroethylene [J]. Environ Toxicol Pharmacol, 2005,11 : 259-271.
  • 7Easterling MR,Evans MV,Kenyon EM. Comparative analysis of software for physiologically based pharmacokinetic modeling:simulation, optimization,and sensitivity analysis [J]. Toxicology Methods, 2000, 10: 203-229.
  • 8DeJongh J, Verhaar H J, Hermens JL. Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs) [J]. Toxicol Sci, 1998,45 : 26-32.
  • 9Dobrev ID,Andersen ME,Yang RS. In silico toxicology:simulating interaction thresholds for human exposure to mixtures of trichloroethylene,tetrachloroethylene,and 1,1,1 -tfichloroethane [J]. Environ Health Perspeet, 2002,110:1031 - 1039.
  • 10El-Masri HA, Kenyon EM. Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites [J], Pharmacokinet Pharmacodyn, 2008,35 : 31-68.

共引文献12

同被引文献72

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部